Genentech Wins FDA OK for Ocrevus Zunovo in Multiple Sclerosis

Roche unit Genentech said the US FDA approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq) for the treatment of relapsing and progressive multiple sclerosis.

• Ocrevus Zunovo is a twice a year 10 minute HCP subcutaneous injection
• Drug combines Ocrevus with Halozyme Therapeutics’ Enhanze delivery system

To view the source of this information, click here

To contact the reporter on this story:
Cameron Baker in Boston at cbaker225@bloomberg.net

To contact the editor responsible for this story:
Zachary Fleming at zfleming2@bloomberg.net

© 2024 Bloomberg L.P. All rights reserved. Used with permission.